Home|Journals|Articles by Year|Audio Abstracts

Original Article

Majmaah J Heal Sci. 2014; 2(1): 15-20

Inverse correlation of Interferon-gamma and CD8+ T Lymphocytes in Tuberculosis Patients

Nadeem Afzal, Khursheed Javaid, Shahid Hussain, Saleem-uz-Zaman Adahmi, Waqas Sami, Ihtzaz Ahmed Malik.


Background & Objectives: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. All over the world TB is one of the leading causes of mortality and morbidity. Interferon-gamma (IFN-γ), at the site of MTB infection, activates macrophages to kill intracellular mycobacteria. CD8+ T cells kill the cells infected by viruses and other intracellular microbes. Diagnostic significance of IFN-γ has been reviewed in latent and active TB. Aim of this study was to determine association between IFN-γ and CD8+ T-cells in the blood of pulmonary TB-patients.

Methods: Study consisted of 54-TB-patients and 38 healthy subjects. Level of IFN-γ was determined by ELISA and percentage of CD8+ T-cells by flow cytometry.

Results: Level of IFN-γ and percentage of CD8+ T-lymphocytes were high in the blood of TB patients compared to control.

Conclusion: TB patients had high level of IFN-γ compared to healthy controls. IFN-γ and CD8+ T cells were negatively correlated with duration of treatment of tuberculosis. There was no difference in percentage of CD8+ T cells in TB patients after 3 months of chemotherapy compared to controls.

Key words: Interferon gamma, Tuberculosis, CD8+ T lymphocytes

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.